Navidea Biopharmaceuticals (NAVB) 10-Q2021 Q1 Quarterly report

Filed: 13 May 21, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Academy, accredited, adjudicate, anniversary, anticancer, book, ceased, Certificate, clarify, comment, cumulative, dataset, disposed, diversity, dramatically, exceed, extinguishment, factual, falling, Food, formal, forthcoming, freestanding, fringe, hearing, holder, immunological, immunology, Immunotherapy, implemented, inadvisable, indemnify, inventory, involuntary, led, mouse, Northwestern, offeree, Official, Paycheck, payload, Preemptive, privilege, proinflammatory, prosecution, prospectively, Reload, repayment, reproducible, respond, retrospective, route, SC, show, statistical, suggested, superior, suspending, synergized, syngeneic, thereof, toxicity, Type, UK, unsatisfactory, violate, vivo, voluntary, winding

Removed: absorption, affinity, alter, alternative, alternatively, AMT, annum, autoimmune, binding, biopsy, Boston, brought, cancellation, categorized, classically, closed, closely, comparator, corporate, CRC, CROI, deadline, Deficiency, demonstrating, deplete, discontinued, distancing, driven, effecting, emergency, employing, Englewood, epidemic, exclusively, execution, expired, flow, foundation, globally, guaranteed, illiquidity, impacting, improvement, instability, Institute, irrespective, Jersey, justify, leased, leverage, limiting, liver, low, lymphatic, manner, marketed, metastatic, Miami, modulate, morale, motivate, NCI, node, noted, occurrence, oncology, originally, overhead, peripheral, personnel, phenotype, positive, precluding, presently, preventative, production, productive, productivity, protect, quantify, quarantine, radioactive, raw, reached, recurrence, reducing, reduction, reference, refund, refundable, refunded, regained, regular, relaxed, repealed, retain, return, semiquantitative, shelf, simultaneously, specific, specificity, split, staging, stating, sublicensed, submitting, substantial, sufficiently, Summit, Sylvan, tested, timeframe, trade, transport, treating, visit, warrant, website

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated NAVB transcripts

NAVB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, 18 U.S.C. SECTION 1350

The undersigned hereby certifies that he is the duly appointed and acting Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer of Navidea Biopharmaceuticals, Inc. (the “Company”) and hereby further certifies as follows:

(1) The periodic report containing financial statements to which this certificate is an exhibit fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the periodic report to which this certificate is an exhibit fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned has executed and delivered this certificate as of the date set forth opposite his signature below.

May 13, 2021		/s/ Jed A. Latkin
		Jed A. Latkin
		Chief Executive Officer, Chief Operating Officer and Chief Financial Officer
		(Principal Executive, Financial and Accounting Officer)